Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
92.25
-2.10 (-2.23%)
Feb 21, 2025, 4:00 PM EST - Market closed
Blueprint Medicines Revenue
In the year 2024, Blueprint Medicines had annual revenue of $508.82M with 104.04% growth. Blueprint Medicines had revenue of $146.37M in the quarter ending December 31, 2024, with 103.41% growth.
Revenue (ttm)
$508.82M
Revenue Growth
+104.04%
P/S Ratio
11.40
Revenue / Employee
$784,012
Employees
649
Market Cap
5.90B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 508.82M | 259.44M | 104.04% |
Dec 31, 2023 | 249.38M | 45.34M | 22.22% |
Dec 31, 2022 | 204.04M | 23.96M | 13.30% |
Dec 31, 2021 | 180.08M | -613.66M | -77.31% |
Dec 31, 2020 | 793.74M | 727.22M | 1,093.37% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BPMC News
- 9 days ago - Blueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results - PRNewsWire
- 17 days ago - Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 - PRNewsWire
- 5 weeks ago - Blueprint Medicines Provides 2025 Outlook and Highlights Strategy for Continued Growth - PRNewsWire
- 2 months ago - Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Blueprint Medicines' Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting - PRNewsWire
- 3 months ago - Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs - Seeking Alpha
- 3 months ago - Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst - Benzinga